

MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies

View Online



[1]

Amori, R.E. et al. 2007. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*. 298, 2 (Jul. 2007). DOI:<https://doi.org/10.1001/jama.298.2.194>.

[2]

Amy Kennedy 2013. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*. 8, 3 (2013). DOI:<https://doi.org/doi:10.1371/journal.pone.0058861>.

[3]

Anderson, B. et al. 2005. The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association.

[4]

Anthony H. Barnett, Jenny Grice 2013. *New Mechanisms in Glucose Control*. BMJ Books; 1 edition.

[5]

Ashwell, S.G. et al. 2006. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*. 23, 3 (Mar. 2006), 285–292.
DOI:<https://doi.org/10.1111/j.1464-5491.2005.01781.x>.

[6]

Atkinson, M.A. 2012. The Pathogenesis and Natural History of Type 1 Diabetes. *Cold Spring Harbor Perspectives in Medicine*. 2, 11 (Nov. 2012), a007641–a007641.
DOI:<https://doi.org/10.1101/cshperspect.a007641>.

[7]

Avery, L. et al. 2012. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*. 35, 12 (Dec. 2012), 2681–2689. DOI:<https://doi.org/10.2337/dc11-2452>.

[8]

Bailey, C.J. et al. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 375, 9733 (Jun. 2010), 2223–2233.
DOI:[https://doi.org/10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2).

[9]

Barry, V.W. et al. 2014. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 56, 4 (Jan. 2014), 382–390.
DOI:<https://doi.org/10.1016/j.pcad.2013.09.002>.

[10]

Bennett, W.L. et al. 2011. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 154, 9 (May 2011).
DOI:<https://doi.org/10.7326/0003-4819-154-9-201105030-00336>.

[11]

Bethel, M.A. et al. 2017. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). *Diabetes Care*. (Jan. 2017).
DOI:<https://doi.org/10.2337/dc16-1135>.

[12]

Beverley M Shields 2015. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*. 5, 11 (2015).
DOI:<https://doi.org/doi:10.1136/bmjopen-2015-009088>.

[13]

Birkeland, K.I. 2015. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 3, 10 (Oct. 2015), 752–753.
DOI:[https://doi.org/10.1016/S2213-8587\(15\)00282-X](https://doi.org/10.1016/S2213-8587(15)00282-X).

[14]

Bretzel, R.G. et al. 2008. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*. 371, 9618 (Mar. 2008), 1073–1084.
DOI:[https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7).

[15]

Brown, J. et al. 1996. Lifestyle interventions for the treatment of women with gestational diabetes. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[16]

Buse, J.B. et al. 2010. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*. 33, 6 (Jun. 2010), 1255–1261.
DOI:<https://doi.org/10.2337/dc09-1914>.

[17]

Buse, J.B. et al. 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*. 374, 9683 (Jul. 2009), 39–47.
DOI:[https://doi.org/10.1016/S0140-6736\(09\)60659-0](https://doi.org/10.1016/S0140-6736(09)60659-0).

[18]

Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 154, 2 (Jan. 2011).

DOI:<https://doi.org/10.7326/0003-4819-154-2-201101180-00300>.

[19]

Capehorn, M. et al. 2017. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia). *Diabetic Medicine*. (Mar. 2017). DOI:<https://doi.org/10.1111/dme.13357>.

[20]

Carver, C. 2006. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*. 32, 6 (Nov. 2006), 910–917. DOI:<https://doi.org/10.1177/0145721706294259>.

[21]

Celia G. Walker 2015. Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. *PLoS ONE*. 10, 7 (2015). DOI:<https://doi.org/doi:10.1371/journal.pone.0131681>.

[22]

Chatterjee, S. and Davies, M. 2015. Type 2 diabetes: recent advances in diagnosis and management. *Prescriber*. 26, 10 (May 2015), 15–21. DOI:<https://doi.org/10.1002/psb.1355>.

[23]

Chimen, M. et al. 2012. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 55, 3 (Mar. 2012), 542–551. DOI:<https://doi.org/10.1007/s00125-011-2403-2>.

[24]

Choudhary, P. et al. 2012. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 29, 7 (Sep. 2012), 280–285. DOI:<https://doi.org/10.1002/pdi.1707>.

[25]

Copeland, K.C. et al. 2013. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS. 131, 2 (Feb. 2013), 364-382. DOI:<https://doi.org/10.1542/peds.2012-3494>.

[26]

Courtney, H. et al. 2017. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Volume 10, (Mar. 2017), 79-87. DOI:<https://doi.org/10.2147/DMSO.S126763>.

[27]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[28]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[29]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[30]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[31]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[32]

Crasto, W. et al. 2016. Handbook of insulin therapies. Adis.

[33]

Daly, H. et al. 2015. Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*. 32, 8 (Oct. 2015), 305–310a. DOI:<https://doi.org/10.1002/pdi.1979>.

[34]

Davies, M. et al. 2005. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 28, 6 (Jun. 2005), 1282–1288. DOI:<https://doi.org/10.2337/diacare.28.6.1282>.

[35]

Davies, M. et al. 2017. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1340–1353. DOI:<https://doi.org/10.1111/dme.13400>.

[36]

Davies, M.J. et al. 2008. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 336, 7642 (Mar. 2008), 491–495. DOI:<https://doi.org/10.1136/bmj.39474.922025.BE>.

[37]

Davies, M.J. and Chatterjee, S. 2017. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. *Nature Reviews Endocrinology*. 13, 6 (Apr. 2017), 317–318. DOI:<https://doi.org/10.1038/nrendo.2017.41>.

[38]

Deacon, C.F. and Lebovitz, H.E. 2016. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. *Diabetes, Obesity and Metabolism*. 18, 4 (Apr. 2016), 333–347. DOI:<https://doi.org/10.1111/dom.12610>.

[39]

Dhatariya, K.K. et al. 2017. The cost of treating diabetic ketoacidosis in the UK: a national

survey of hospital resource use. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1361–1366.
DOI:<https://doi.org/10.1111/dme.13427>.

[40]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 375, 9733 (Jun. 2010), 2234–2243.
DOI:[https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

[41]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 375, 9733 (Jun. 2010), 2234–2243.
DOI:[https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

[42]

Dungan, K.M. et al. 2014. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 384, 9951 (Oct. 2014), 1349–1357.
DOI:[https://doi.org/10.1016/S0140-6736\(14\)60976-4](https://doi.org/10.1016/S0140-6736(14)60976-4).

[43]

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials-
ClinicalKey:
<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>.

[44]

Evans, M. et al. 2011. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*. 13, 8 (Aug. 2011), 677–684.
DOI:<https://doi.org/10.1111/j.1463-1326.2011.01395.x>.

[45]

Frandsen, C.S.S. and Madsbad, S. 2014. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 31, 11 (Nov. 2014), 1293–1300.
DOI:<https://doi.org/10.1111/dme.12561>.

[46]

Funnell, M.M. 2007. Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*. 25, 1 (Jan. 2007), 36–38. DOI:<https://doi.org/10.2337/diaclin.25.1.36>.

[47]

Gallwitz, B. et al. 2012. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 380, 9840 (Aug. 2012), 475–483.
DOI:[https://doi.org/10.1016/S0140-6736\(12\)60691-6](https://doi.org/10.1016/S0140-6736(12)60691-6).

[48]

Garber, A.J. et al. 2006. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*. 8, 1 (Jan. 2006), 58–66.
DOI:<https://doi.org/10.1111/j.1463-1326.2005.00563.x>.

[49]

Garber, A.J. et al. 2012. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *The Lancet*. 379, 9825 (Apr. 2012), 1498–1507.
DOI:[https://doi.org/10.1016/S0140-6736\(12\)60205-0](https://doi.org/10.1016/S0140-6736(12)60205-0).

[50]

Garber, A.J. et al. 2007. Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*. 9, 5 (Sep. 2007), 630–639.
DOI:<https://doi.org/10.1111/j.1463-1326.2006.00654.x>.

[51]

Gough, S.C.L. 2007. A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*. 77, 1 (Jul. 2007), 1–15. DOI:<https://doi.org/10.1016/j.diabres.2006.10.015>.

[52]

Gough, S.C.L. et al. 2013. Insulin degludec: overview of a novel ultra long-acting basal insulin. *Diabetes, Obesity and Metabolism*. 15, 4 (Apr. 2013), 301–309. DOI:<https://doi.org/10.1111/dom.12052>.

[53]

Grammes, J. et al. 2017. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. (Aug. 2017). DOI:<https://doi.org/10.1111/dme.13506>.

[54]

Gray, L.J. et al. 2014. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*. 104, 3 (Jun. 2014), 451–458. DOI:<https://doi.org/10.1016/j.diabres.2014.03.018>.

[55]

Gray, L.J. et al. 2012. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 55, 12 (Dec. 2012), 3238–3244. DOI:<https://doi.org/10.1007/s00125-012-2725-8>.

[56]

Green, J.B. et al. 2015. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 373, 3 (Jul. 2015), 232–242. DOI:<https://doi.org/10.1056/NEJMoa1501352>.

[57]

Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal* . 92, 1085 (Mar. 2016), 152–164. DOI:<https://doi.org/10.1136/postgradmedj-2015-133716>.

[58]

Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal* . 92, 1085 (Mar. 2016), 152–164. DOI:<https://doi.org/10.1136/postgradmedj-2015-133716>.

[59]

Hadjiconstantinou, M. et al. 2016. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 18, 10 (Oct. 2016). DOI:<https://doi.org/10.2196/jmir.5991>.

[60]

Hartman, Y.A.W. et al. 2017. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care*. 40, 9 (Sep. 2017), e120–e121. DOI:<https://doi.org/10.2337/dc17-0787>.

[61]

Heinonen, I. et al. 2013. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 3, 6 (May 2013). DOI:<https://doi.org/10.1136/bmjopen-2013-002901>.

[62]

Heller, S.R. et al. 2004. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*. 21, 7 (Jul. 2004), 769–775. DOI:<https://doi.org/10.1111/j.1464-5491.2004.01244.x>.

[63]

Henson, Joseph 2014. Associations of Sedentary Time with Fat Distribution in a High-Risk

Population. (Nov. 2014).

[64]

Hermansen, K. et al. 2006. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*. 29, 6 (Jun. 2006), 1269–1274. DOI:<https://doi.org/10.2337/dc05-1365>.

[65]

Holman, R.R. et al. 2007. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 357, 17 (Oct. 2007), 1716–1730. DOI:<https://doi.org/10.1056/NEJMoa075392>.

[66]

Holman, R.R. and Turner, R.C. 1985. A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*. 2, 1 (Jan. 1985), 45–53. DOI:<https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>.

[67]

Home, P.D. 2012. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*. 14, 9 (Sep. 2012), 780–788. DOI:<https://doi.org/10.1111/j.1463-1326.2012.01580.x>.

[68]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[69]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[70]

Htike, Z.Z. et al. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. 19, 4 (Apr. 2017), 524-536.
DOI:<https://doi.org/10.1111/dom.12849>.

[71]

Htike, Z.Z. et al. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. 19, 4 (Apr. 2017), 524-536.
DOI:<https://doi.org/10.1111/dom.12849>.

[72]

Htike, Z.Z. et al. 2016. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. *British Journal of Diabetes*. 16, 3 (Sep. 2016). DOI:<https://doi.org/10.15277/bjd.2016.091>.

[73]

Inzucchi, S.E. et al. 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 38, 1 (Jan. 2015), 140-149. DOI:<https://doi.org/10.2337/dc14-2441>.

[74]

Ismail-Beigi, F. 2012. Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 366, 14 (Apr. 2012), 1319-1327.
DOI:<https://doi.org/10.1056/NEJMcp1013127>.

[75]

John M Jakicic 2005. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition*. 82, 1 (Jan. 2005), 226S-229S.

[76]

Johnston, B.C. et al. 2014. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 312, 9 (Sep. 2014).
DOI:<https://doi.org/10.1001/jama.2014.10397>.

[77]

Jones, A.G. and Hattersley, A.T. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 30, 7 (Jul. 2013), 803–817.
DOI:<https://doi.org/10.1111/dme.12159>.

[78]

Kamlesh Khunti 2015. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE*. 10, 9 (2015). DOI:<https://doi.org/doi:10.1371/journal.pone.0135702>.

[79]

Kenneth Hodson 2010. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*. 3, 4 (2010). DOI:<https://doi.org/doi:10.1258/om.2010.100025>.

[80]

Latika Sahu 2009. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*. 2, 4 (2009). DOI:<https://doi.org/doi:10.1258/om.2009.080049>.

[81]

Lee, I.-M. 2010. Physical Activity and Weight Gain Prevention. *JAMA*. 303, 12 (Mar. 2010). DOI:<https://doi.org/10.1001/jama.2010.312>.

[82]

Leff, D.R. and Heath, D. 2009. Surgery for obesity in adulthood. *BMJ*. 339, sep22 1 (Sep. 2009), b3402–b3402. DOI:<https://doi.org/10.1136/bmj.b3402>.

[83]

Levin, P.A. et al. 2017. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. Volume 10, (Apr. 2017), 123–139.
DOI:<https://doi.org/10.2147/DMSO.S130834>.

[84]

Mäkimattila, S. et al. 1999. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*. 42, 4 (Mar. 1999), 406–412. DOI:<https://doi.org/10.1007/s001250051172>.

[85]

Marre, M. et al. 2009. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*. 26, 3 (Mar. 2009), 268–278.
DOI:<https://doi.org/10.1111/j.1464-5491.2009.02666.x>.

[86]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 311–322.
DOI:<https://doi.org/10.1056/NEJMoa1603827>.

[87]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 311–322.
DOI:<https://doi.org/10.1056/NEJMoa1603827>.

[88]

Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 375, 19 (Nov. 2016), 1834–1844.
DOI:<https://doi.org/10.1056/NEJMoa1607141>.

[89]

Merlin C. Thomas 2016. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*. 7, 3 (2016). DOI:[https://doi.org/doi: 10.1007/s13300-016-0189-4](https://doi.org/doi:10.1007/s13300-016-0189-4).

[90]

Michael Riddell 2009. Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology (Online)*. 3, 4 (2009). DOI:[https://doi.org/doi: 10.1177/193229680900300439](https://doi.org/doi:10.1177/193229680900300439).

[91]

Min, S.H. et al. 2017. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 33, 1 (Jan. 2017). DOI:<https://doi.org/10.1002/dmrr.2818>.

[92]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 109, 2 (Aug. 2015), 378–388. DOI:<https://doi.org/10.1016/j.diabres.2015.05.025>.

[93]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 109, 2 (Aug. 2015), 378–388. DOI:<https://doi.org/10.1016/j.diabres.2015.05.025>.

[94]

Moreno-Castilla, C. et al. 2016. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 16, 4 (Apr. 2016). DOI:<https://doi.org/10.1007/s11892-016-0717-7>.

[95]

Nathan, D.M. et al. 2006. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 29, 8 (Aug. 2006), 1963–1972. DOI:<https://doi.org/10.2337/dc06-9912>.

[96]

Nauck, M. et al. 2014. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 37, 8 (Aug. 2014), 2149–2158. DOI:<https://doi.org/10.2337/dc13-2761>.

[97]

Nauck, M. 2016. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*. 18, 3 (Mar. 2016), 203–216. DOI:<https://doi.org/10.1111/dom.12591>.

[98]

Nauck, M.A. et al. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 9, 2 (Mar. 2007), 194–205. DOI:<https://doi.org/10.1111/j.1463-1326.2006.00704.x>.

[99]

Nauck, M.A. and Meier, J.J. 2016. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 4, 6 (Jun. 2016), 525–536. DOI:[https://doi.org/10.1016/S2213-8587\(15\)00482-9](https://doi.org/10.1016/S2213-8587(15)00482-9).

[100]

Nissen, S.E. and Wolski, K. 2007. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 356,

24 (Jun. 2007), 2457–2471. DOI:<https://doi.org/10.1056/NEJMoa072761>.

[101]

Nolan, C.J. et al. 2015. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 64, 3 (Mar. 2015), 673–686. DOI:<https://doi.org/10.2337/db14-0694>.

[102]

Paul Craddy 2014. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*. 5, 1 (2014). DOI:<https://doi.org/doi:10.1007/s13300-014-0061-3>.

[103]

Persaud, S.J. and Jones, P.M. 2016. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 375, 11 (Sep. 2016), 1090–1092. DOI:<https://doi.org/10.1056/NEJMcibr1607950>.

[104]

Postnatal testing following gestational diabetes- ClinicalKey:
<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>.

[105]

Qin, L. et al. 2010. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 25, 1 (Jan. 2010), 5–12. DOI:<https://doi.org/10.1007/s10654-009-9395-y>.

[106]

Raskin, P. et al. 2005. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*. 28, 2 (Feb. 2005), 260–265. DOI:<https://doi.org/10.2337/diacare.28.2.260>.

[107]

Resources and tools:

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>.

[108]

Resources and tools:

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>.

[109]

Resources and tools:

<http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>.

[110]

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein 2016. Textbook of Diabetes. John Wiley.

[111]

Richter, B. and Neises, G. 1996. 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[112]

Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 36, 9 (Sep. 2013), 2489-2496.
DOI:<https://doi.org/10.2337/dc12-2454>.

[113]

Rinki Murphy 2015. Monogenic diabetes and pregnancy. *Obstetric Medicine*. 8, 3 (2015).
DOI:<https://doi.org/doi:10.1177/1753495X15590713>.

[114]

Rizos, C.V. et al. 2016. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 90, 8 (Aug. 2016), 1861–1881.
DOI:<https://doi.org/10.1007/s00204-016-1737-4>.

[115]

Rosenstock, J. et al. 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia*. 51, 3 (Mar. 2008), 408–416.
DOI:<https://doi.org/10.1007/s00125-007-0911-x>.

[116]

Rosenstock, J. et al. 2013. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 36, 10 (Oct. 2013), 2945–2951. DOI:<https://doi.org/10.2337/dc12-2709>.

[117]

Rotz, M.E. et al. 2015. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 69, 5 (May 2015), 531–549.
DOI:<https://doi.org/10.1111/ijcp.12572>.

[118]

Ryder, B. et al. 2013. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*. 30, 9 (Nov. 2013), 388–391.
DOI:<https://doi.org/10.1002/pdi.1816>.

[119]

S M Attard 2015. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutrition & Diabetes*. 5, 6 (2015). DOI:<https://doi.org/doi:10.1038/nutd.2015.16>.

[120]

Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com:
<http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>.

[121]

Sallis, J.F. et al. 2016. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 388, 10051 (Sep. 2016), 1325–1336.
DOI:[https://doi.org/10.1016/S0140-6736\(16\)30581-5](https://doi.org/10.1016/S0140-6736(16)30581-5).

[122]

Samuel, V.T. and Shulman, G.I. 2012. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell*. 148, 5 (Mar. 2012), 852–871.
DOI:<https://doi.org/10.1016/j.cell.2012.02.017>.

[123]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 376, 7 (Feb. 2017), 641–651.
DOI:<https://doi.org/10.1056/NEJMoa1600869>.

[124]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 366, 17 (Apr. 2012), 1567–1576.
DOI:<https://doi.org/10.1056/NEJMoa1200225>.

[125]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 366, 17 (Apr. 2012), 1567–1576.
DOI:<https://doi.org/10.1056/NEJMoa1200225>.

[126]

Schwartz, S.S. et al. 2016. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*. 39, 2 (Feb. 2016), 179–186. DOI:<https://doi.org/10.2337/dc15-1585>.

[127]

Simmons, R.K. et al. 2016. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. *Health Technology Assessment*. 20, 64 (Aug. 2016), 1–86. DOI:<https://doi.org/10.3310/hta20640>.

[128]

Sivasubramaniyam, S. et al. 2017. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1456–1460. DOI:<https://doi.org/10.1111/dme.13438>.

[129]

Sjöström, L. et al. 2004. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 351, 26 (Dec. 2004), 2683–2693. DOI:<https://doi.org/10.1056/NEJMoa035622>.

[130]

Srinivasan, B.T. et al. 2008. Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*. 84, 996 (Oct. 2008), 524–531. DOI:<https://doi.org/10.1136/pgmj.2008.067918>.

[131]

Srinivasan, B.T. and Davies, M. 2014. Glycaemic management of type 2 diabetes. *Medicine*. 42, 12 (Dec. 2014), 711–717. DOI:<https://doi.org/10.1016/j.mpmed.2014.09.011>.

[132]

Srinivasan, P. et al. 2007. Islet cell transplantation. *Postgraduate Medical Journal*. 83, 978 (Apr. 2007), 224–229. DOI:<https://doi.org/10.1136/pgmj.2006.053447>.

[133]

Steven, S. et al. 2016. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 39, 5 (May 2016), 808–815. DOI:<https://doi.org/10.2337/dc15-1942>.

[134]

Steven, S. and Taylor, R. 2015. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 32, 9 (Sep. 2015), 1149–1155. DOI:<https://doi.org/10.1111/dme.12722>.

[135]

Stewart, Z.A. et al. 2016. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 375, 7 (Aug. 2016), 644–654. DOI:<https://doi.org/10.1056/NEJMoa1602494>.

[136]

Swinnen, S.G. et al. 1996. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[137]

Tanner, M. 2016. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 165, 4 (Aug. 2016). DOI:<https://doi.org/10.7326/ACPJC-2016-165-4-020>.

[138]

Tao, L. et al. 2015. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*. 32, 7 (Jul. 2015), 907–919. DOI:<https://doi.org/10.1111/dme.12711>.

[139]

Umpierre, D. 2011. Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*. 305, 17 (May 2011). DOI:<https://doi.org/10.1001/jama.2011.576>.

[140]

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care:
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>.

[141]

Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 34, 9 (Sep. 2017), 1205–1211.
DOI:<https://doi.org/10.1111/dme.13379>.

[142]

Vloemans, A.F. et al. 2017. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1470–1476. DOI:<https://doi.org/10.1111/dme.13429>.

[143]

Wanner, C. et al. 2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 323–334.
DOI:<https://doi.org/10.1056/NEJMoa1515920>.

[144]

WHO 2011 Use of glycated haemoglobin (HbA_{1c}) in the diagnosis of diabetes mellitus:
http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/.

[145]

Yeh, J.S. et al. 2016. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 375, 12 (Sep. 2016), 1187–1189. DOI:<https://doi.org/10.1056/NEJMclde1515935>.

[146]

Yki-Järvinen, H. et al. 2006. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*. 49, 3 (Mar. 2006), 442–451. DOI:<https://doi.org/10.1007/s00125-005-0132-0>.

[147]

Young, L.A. and Buse, J.B. 2014. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*. 384, 9961 (Dec. 2014), 2180–2181. DOI:[https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4).

[148]

Young-Hyman, D. et al. 2017. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*. 40, 2 (Feb. 2017), 287.1-287. DOI:<https://doi.org/10.2337/dc17-er02>.

[149]

Zaccardi, F. et al. 2016. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 92, 1084 (Feb. 2016), 63–69. DOI:<https://doi.org/10.1136/postgradmedj-2015-133281>.

[150]

Zinman, B. et al. 2011. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*. 377, 9769 (Mar. 2011), 924–931. DOI:[https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7).

[151]

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics.

[152]

2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 375, 18 (Nov. 2016), 1799–1802. DOI:<https://doi.org/10.1056/NEJMc1611290>.

[153]

2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 18 (Nov. 2016), 1797–1799. DOI:<https://doi.org/10.1056/NEJMc1611289>.

[154]

2015. Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 38, 8 (Aug. 2015), 1583–1591. DOI:<https://doi.org/10.2337/dc15-0279>.

[155]

4AD. Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes.

[156]

2015. Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care*. 38, Supplement_1 (Jan. 2015), S4–S4. DOI:<https://doi.org/10.2337/dc15-S003>.

[157]

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.